Anti-counterfeiting in pharmaceuticals refers to the technologies, processes and controls used to prevent, detect and investigate medicines that are falsely presented as genuine. The objective is not limited to protecting a brand name or reducing revenue loss. It is also about protecting patients from medicines that may contain the wrong ingredient, an incorrect dose, no active ingredient or undeclared substances.
Anti-counterfeiting in pharmaceuticals refers to the technologies, processes and controls used to prevent, detect and investigate medicines that are falsely presented as genuine. The objective is not limited to protecting a brand name or reducing revenue loss. It is also about protecting patients from medicines that may contain the wrong ingredient, an incorrect dose, no active ingredient or undeclared substances.
A falsified medicine may look convincing because counterfeiters can copy colours, logos, batch details, barcodes, cartons and even visible security features. For this reason, appearance alone is not a reliable test. An effective pharmaceutical anti-counterfeiting programme connects the physical medicine pack with a unique identity, a secure verification method, supply-chain records and a clear process for responding when something appears suspicious.
The strongest programmes use several complementary controls rather than relying on one sticker, code or database. Secure packaging can help users inspect the product, serialization can distinguish one pack from another, digital authentication can confirm whether an identity exists in an authorised system, and track and trace can record selected movements through the supply chain. Supplier controls, data security, regulatory alignment and incident response are equally important because technology loses value when the surrounding process is weak.
The terms counterfeit, falsified and substandard are often used together, but they describe different problems. A falsified medicine deliberately misrepresents its identity, composition or source. It may carry the name of a false manufacturer, contain an incorrect amount of active ingredient, use copied packaging or display altered batch information. A duplicated serial number or copied medicine authentication code may also be used to make the pack appear legitimate.
A substandard medicine, by comparison, is an authorised product that fails to meet the required quality standards or specifications. The cause may be a manufacturing failure, inadequate quality control, poor storage, temperature exposure, transport damage or packaging failure. A medicine can therefore be genuine but still substandard.
The word counterfeit is commonly associated with trademark or intellectual-property infringement. In a public-health context, falsified medicine is often the more precise term when the product deliberately misrepresents what it is or where it came from. Anti-counterfeiting systems mainly address deliberate falsification, substitution and unauthorised distribution, while pharmaceutical quality systems remain necessary for detecting genuine medicines that fail to meet specification.
Pharmaceutical products can be valuable, widely distributed and difficult for patients to assess. A professional-looking carton does not confirm that the medicine inside is genuine. Falsified products may enter the market through unauthorised manufacturers, unapproved suppliers, compromised distributors, stolen shipments, reused packaging, fraudulent returns, product substitution, unlicensed online pharmacies or diversion from the intended market. Copied serial numbers and QR codes can make these products even harder to identify.
The consequences extend beyond commercial loss. A compromised medicine can delay effective treatment, expose patients to avoidable harm and undermine trust in healthcare systems. Pharmaceutical companies may also face investigations, recalls, regulatory scrutiny, channel disputes and long-term damage to their reputation. A suitable protection strategy must therefore secure both the physical package and the digital identity linked to it.
A customised security hologram creates optical effects that are difficult to reproduce accurately with ordinary printing equipment. Depending on the design, it may include multiple visual planes, kinetic movement, microtext, hidden images, demetallised areas, serial numbers, QR-code integration and tamper-evident materials.
The design should be unique to the brand and product. Generic holographic stickers offer a weaker reference because similar materials may be commercially available. Veritech’s secure hologram solutions can combine visible authentication with covert and tamper-evident features.
A hologram cannot confirm the chemical composition of a medicine. Its purpose is to support visual authentication and make reproduction more difficult. It should work alongside quality controls, serialization and digital verification rather than replace them.
Security printing adds details that standard scanners and commercial printers cannot reproduce easily. Pharmaceutical labels and cartons may use UV-fluorescent or infrared-responsive inks, thermochromic or photochromic effects, colour-shifting elements, microtext, fine-line patterns, anti-scan backgrounds, hidden images and machine-readable features.
Different features serve different users. A consumer may recognise a visible colour change, while an authorised inspector may use ultraviolet light or a compatible reader to verify a covert response. Veritech’s high-security printing solutions can support pharmaceutical packaging, authentication labels and protected documents.
The selected feature must be tested on the final packaging material. Adhesives, coatings, production speed, temperature, storage conditions and surface texture can all affect performance. A feature that works well in a laboratory sample may behave differently on a live packaging line.
Tamper-evident packaging shows visible evidence when someone attempts to open, remove, transfer or reuse a pharmaceutical package. Depending on the construction, the label may break into pieces, leave a VOID message, transfer a pattern, damage the surface or become permanently distorted.
These solutions can be used on cartons, bottles, vials, closures and secondary packaging that might otherwise be opened and resealed. The material should match the packaging surface, closure system and likely method of interference. Veritech’s tamper-evident seal solutions can be customised for different pharmaceutical formats.
Tamper-evident does not mean tamper-proof. A seal cannot make interference impossible. Its role is to make interference easier to notice so that the product can be isolated and examined before use or resale.
Pharmaceutical serialization assigns a unique identity to an individual medicine pack or another defined packaging unit. The identity may appear as a data matrix, QR code, security barcode, alphanumeric serial number, RFID tag or NFC tag. The digital record behind the identifier can connect the pack with its product name, batch number, manufacturing date, expiry date, production facility, destination market and distribution status.
This allows a company to distinguish one pack from another instead of identifying only the product type. Serialization can support duplicate-code detection, recalls, distribution investigations and product authentication. However, printing a number is only the beginning. The manufacturer must control how identities are generated, issued, printed, inspected, activated, rejected, deactivated and archived.
Unused, damaged or rejected serialized labels must be reconciled and securely destroyed or disabled. Without this control, genuine identities could be applied to unauthorised packaging and make a falsified product appear valid.
A serialized QR code can give pharmacists, distributors and consumers access to a digital verification page. When the code is scanned, the system may check whether the identity exists, whether it belongs to the expected medicine, whether it has been activated, whether it has been scanned before and whether the batch has expired, been recalled or shown an unusual scan pattern.
An ordinary QR code that sends every user to the same webpage does not authenticate an individual medicine pack. The image can be copied and printed on many packages. A stronger approach uses a unique and unpredictable identity linked to a controlled database.
The verification response should also be clear. A message such as “Thank you for scanning” does not confirm authentication. The page should explain whether the identity is valid, invalid, previously scanned, deactivated, linked to a recall or under review. Veritech’s product authentication and verification solution can connect medicine packaging with controlled digital records.
A copied genuine code may still produce a valid response during its first unauthorised use. This is why QR-code authentication should be combined with duplicate-scan monitoring, tamper evidence, secure holograms and supply-chain records.
Pharmaceutical track and trace records selected events as a medicine moves through manufacturing and distribution. Tracking shows the latest recorded status of a product, while tracing helps reconstruct where it came from and which organisations handled it.
A typical history may include code generation, packaging, aggregation, dispatch, warehouse receipt, distributor transfer, pharmacy receipt, product verification, return, recall and disposal. These events can help identify duplicate identities, unexplained movement and stock found outside an authorised route.
A pharmaceutical track-and-trace solution does not automatically prove that the medicine inside a package is genuine. Its value depends on secure identities, accurate data and reliable event capture. Visibility may also vary according to where scanning occurs and how quickly supply-chain partners transmit information.
Radio-frequency identification and near-field communication can support faster product identification and verification. RFID can read several tagged units without direct line of sight, making it useful for selected inventory, shipment, warehouse, cold-chain and return-management applications. NFC supports short-range interaction with a compatible smartphone or reader and may provide product verification, controlled information or digital engagement.
These technologies generally cost more than printed codes, so they are often more suitable for high-value medicines, specialised shipments, reusable logistics assets or controlled distribution programmes. Their value should be assessed against the product risk and the operational benefit they provide.
An RFID or NFC tag does not automatically contain patient medical information. Privacy risk depends on what data is collected, how it is linked and who can access it. Companies should avoid collecting personal or health information unless it is necessary and protected by suitable access, security and retention controls.
Blockchain can create a shared, append-only record of selected supply-chain transactions. It may be useful where several independent organisations need access to a common record without placing full control in one organisation’s database.
However, blockchain does not prove that a physical medicine is genuine, prevent a visible code from being copied, confirm that the original data was accurate or verify that the medicine was stored correctly. It also does not replace tamper-evident packaging, supplier audits or quality controls.
Blockchain protects recorded information from certain types of alteration, but it cannot independently inspect a medicine or correct inaccurate information entered at the start. For many pharmaceutical programmes, a securely governed central database may be simpler and more cost-effective. Brands comparing the available options can review Veritech’s guide to holograms, NFC and blockchain.
| Security layer | Example technology | Primary purpose |
| Visual authentication | Custom hologram | Supports an immediate visual check |
| Covert authentication | UV ink or microtext | Supports authorised inspection |
| Packaging protection | Tamper-evident seal | Reveals opening or label transfer |
| Unique identity | Serialized label | Distinguishes individual packs |
| Digital verification | QR authentication | Checks identity against a database |
| Supply-chain visibility | Track and trace | Records selected product movements |
| Automated identification | RFID or NFC | Supports faster reading and verification |
| Investigation | Forensic marker | Provides specialist evidence |
The correct combination depends on the medicine, packaging format, target market, patient risk and intended verification users. A lower-risk over-the-counter product may not need the same controls as a high-value oncology medicine, injectable product or temperature-sensitive shipment.
The objective is not to add every available technology. It is to select complementary controls that address realistic threats without making verification unnecessarily complex or expensive.
Technology only creates value when it supports a controlled operational process. Security labels, cartons, hologram masters and serial-number files must be reconciled, and unused or rejected materials must be returned, deactivated or destroyed through a documented procedure. Otherwise, genuine security materials may leak into unauthorised channels.
Supplier qualification is equally important. Pharmaceutical companies should assess ingredient suppliers, contract manufacturers, packaging vendors, warehouses, logistics providers and distributors. The review should cover licences, site security, subcontracting, data access, waste handling, employee permissions and production reconciliation.
Verification instructions must also match the user. Pharmacists, distributors and consumers need simple guidance on where the security feature appears, how it should behave, how to verify the identity and what to do after a suspicious result. Covert and forensic details should remain restricted to authorised teams.
A duplicated code, damaged seal or unexpected scan should trigger a defined incident-response process. The product may need to be quarantined while manufacturing records, shipment data, scan history and physical security features are reviewed. Depending on the risk, the company may also need to contact the authorised distributor, arrange laboratory analysis and report a confirmed case to the relevant authority. An authentication system is only useful when teams understand how to respond to the information it produces.
Pharmaceutical serialization, traceability, labelling and reporting requirements vary between countries. Different markets may require different package-level identifiers, verification processes, anti-tampering devices, transaction records or reporting systems.
A pharmaceutical company should therefore design its programme around the countries in which the medicine is manufactured, distributed and sold. A common technical framework may be possible, but local regulatory, reporting and data-retention requirements should be reviewed before implementation.
Cost and infrastructure are often the first concerns. Serialization, variable-data printing, inspection systems, software integration and field verification require investment. Smaller manufacturers may need to begin with the products or markets carrying the highest patient, regulatory or commercial risk.
Legacy-system integration can also be difficult. Authentication platforms may need to exchange data with enterprise resource planning systems, manufacturing execution systems, packaging lines, warehouse platforms, distributor systems and regulatory repositories. Poor integration can create incomplete records, duplicate work and conflicting product statuses.
International coordination adds another layer of complexity because falsified medicines can move across borders while enforcement powers remain country-specific. Effective action may require cooperation among manufacturers, customs authorities, regulators, distributors, law-enforcement agencies and online platforms.
Data security and privacy must be built into the system from the beginning. Authentication databases may contain sensitive production and distribution information, so businesses need appropriate access controls, encryption, secure interfaces, audit logs, backups, retention rules and incident-response procedures. Consumer-facing verification should avoid collecting unnecessary personal or medical information.
User adoption is another practical issue. A technically strong authentication platform has limited value when patients, pharmacists or distributors do not understand how to use it. Instructions should be brief, visible and connected to a recognisable brand-owned verification experience.
Pharmaceutical anti-counterfeiting is moving towards connected packaging that combines physical security with controlled digital identities. Secure holograms, tamper-evident materials and digital authentication are increasingly being designed as one verification journey instead of separate projects.
Risk-based packaging design will also become more important. Applying the same security label to every medicine is rarely efficient. Companies will increasingly consider patient risk, product value, package type, distribution complexity, market exposure and the product’s history of falsification before choosing a security level.
Advanced scan analytics can help brands identify duplicate-code clusters, unexpected scan locations, excessive verification attempts, codes scanned before dispatch and products appearing outside authorised markets. These signals can guide investigations, but they should not automatically be treated as proof of counterfeiting.
Nano-optical structures, specialised taggants and material-level signatures may provide stronger covert or forensic verification for selected high-risk products. Their practical value will depend on cost, scalability, verification equipment and compatibility with existing packaging lines.
As pharmaceutical packaging becomes more connected, data governance will be just as important as the visible security feature. Businesses will need tighter control over who can generate, print, activate, deactivate and access product identities.
Veritech develops physical and digital solutions for pharmaceutical product authentication, tamper evidence and supply-chain visibility. Depending on the medicine and its risk profile, the solution may combine custom security holograms, secure pharma labels, security inks, tamper-evident seals, serialized labels, security barcode labels, QR-code authentication, variable-data printing, product verification, track-and-trace integration and covert security features.
Pharmaceutical companies can explore Veritech’s medical and healthcare solutions or review the guide to choosing an anti-counterfeit label for pharmaceutical products.
The appropriate solution should be selected after reviewing the medicine, packaging material, manufacturing process, target market, distribution network and intended verification users.
It is the use of physical, digital, operational and legal controls to prevent, detect and investigate falsified medicines and packaging.
Common options include security holograms, security inks, tamper-evident seals, serialization, QR authentication, RFID, NFC and pharmaceutical track-and-trace systems.
No. Serialization assigns a unique identity to a medicine pack. Authentication checks whether that identity is valid and linked to the expected product.
An ordinary QR code cannot. A unique code connected to a secure database can support verification, but it should be combined with monitoring and physical security features.
Custom holograms provide useful visual authentication. Their value increases when combined with covert features, serialization, tamper evidence and digital verification.
It is packaging designed to show visible evidence when a label, closure, carton or seal has been opened or interfered with.
Anti-counterfeiting in pharmaceuticals cannot be solved by adding one sticker, QR code or software platform. An effective programme connects secure packaging with unique product identities, reliable supply-chain information, qualified partners and a clear investigation process.
Holograms, security inks, tamper-evident packaging, serialization, QR authentication and track and trace each address a different risk. When these controls work together, pharmaceutical companies can make falsification more difficult, identify suspicious products earlier and strengthen patient confidence in the legitimate medicine supply chain.
